Expanded Indication for Darzalex in Relapsed or Refractory Multiple Myeloma
On November 21, 2016, Janssen Biotech, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) for use in combination with two standard-of-care regimens: lenalidomide and dexamethasone, or bortezomib and dexamethasone. This approval specifically applies to the treatment of patients with multiple myeloma who have received at least one prior therapy. Multiple myeloma remains an incurable blood cancer characterized by the uncontrollable growth of malignant plasma cells in the bone marrow, making the introduction of versatile combination therapies a critical advancement for patients facing disease progression.
Accelerated Regulatory Path and Breakthrough Designation
The FDA’s decision follows an efficient regulatory timeline, coming just three months after the supplemental Biologics License Application (sBLA) was submitted in August 2016. Recognizing the potential of Darzalex to provide substantial improvement over existing therapies, the FDA had previously granted the regimen Breakthrough Therapy Designation in July 2016. As the world’s first approved CD38-directed cytolytic antibody, Darzalex was initially approved in 2015 as a monotherapy for heavily pre-treated patients; this new approval significantly moves its utility earlier in the treatment continuum as a potential backbone therapy.
Efficacy of Darzalex in Combination with Immunomodulatory Agents
The approval is heavily supported by results from the Phase 3 POLLUX (MMY3003) clinical study, which evaluated Darzalex in combination with lenalidomide and dexamethasone. In this trial, the Darzalex-based triplet reduced the risk of disease progression or death by 63 percent compared to lenalidomide and dexamethasone alone ($HR=0.37$; $95% ext{ CI: } 0.27-0.52$; $p<0.0001$). At a median follow-up of 13.5 months, the median progression-free survival (PFS) for the Darzalex arm had not yet been reached, significantly outperforming the 18.4 months observed in the control group. Furthermore, the overall response rate (ORR) reached 91 percent, with the rate of complete response (CR) more than doubling compared to the standard doublet therapy.
Clinical Performance with Proteasome Inhibitor Regimens
A second Phase 3 study, CASTOR (MMY3004), demonstrated the efficacy of Darzalex when combined with bortezomib and dexamethasone. In patients who had received a median of two prior lines of therapy, this combination reduced the risk of disease progression or death by 61 percent ($HR=0.39$; $95% ext{ CI: } 0.28-0.53$; $p<0.0001$). Similar to the POLLUX results, the median PFS for the Darzalex group in the CASTOR study had not been reached at a follow-up of 7.4 months, whereas the control group showed a median PFS of 7.2 months. The addition of Darzalex also significantly improved the ORR to 79 percent and doubled the CR rate from 7 percent to 14 percent.
Impact on the Multiple Myeloma Treatment Paradigm
The integration of Darzalex with the two most widely used classes of treatment—immunomodulatory agents and proteasome inhibitors—represents a major shift in managing relapsed or refractory disease. Clinical investigators emphasize that Darzalex’s ability to significantly improve PFS and depth of response across different combinations highlights its versatility. By establishing a new backbone for therapy, this approval provides physicians with a highly effective tool to extend the duration of response for patients who have already experienced at least one prior treatment failure, potentially changing the long-term clinical trajectory of the disease.
